• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Dose-response relation: relevance for clinical practice].

作者信息

Klinkhardt U, Harder S

机构信息

Institut für Klinische Pharmakologie, Universitätsklinik Frankfurt am Main.

出版信息

Med Klin (Munich). 1998 Dec 15;93(12):744-9. doi: 10.1007/BF03044815.

DOI:10.1007/BF03044815
PMID:10024846
Abstract

Dose-finding studies are performed routinely in patients and--if appropriate surrogate models exist--also in healthy volunteers. Such studies aim at establishing the optimal dose range for further clinical studies on the efficacy and the risk-benefit ratio of a new drug. The dose-response relationship of a drug is most often described by a sigmoidal curve. Its parameters include the mean effective dose, the maximal effect and the steepness. Interpretation of such curves should be done in the context of the intended clinical indications of the drug. The risk-benefit ratio of a drug can be assessed by overlapping the dose-response curve of wanted and unwanted clinical effects, again, any overlapping (which can be described e.g. by the therapeutic index) should be seen in the context of the indication and available therapeutic alternatives.

摘要

相似文献

1
[Dose-response relation: relevance for clinical practice].
Med Klin (Munich). 1998 Dec 15;93(12):744-9. doi: 10.1007/BF03044815.
2
[Dose-response relationship: relevance for medical practice].剂量反应关系:对医学实践的相关性
Med Klin (Munich). 2000 May;95(1 Spec No):9-14.
3
Dose-response relationship in the treatment of gastrointestinal disorders.胃肠道疾病治疗中的剂量-反应关系。
Z Gastroenterol. 1989 Aug;27(8):438-43.
4
Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.临床药代动力学:从监管角度看当前要求及未来展望
Xenobiotica. 1993 Nov;23(11):1159-93. doi: 10.3109/00498259309059432.
5
Using exposure-response and biomarkers to streamline early drug development.利用暴露-反应关系和生物标志物简化早期药物研发。
Ernst Schering Res Found Workshop. 2007(59):47-63. doi: 10.1007/978-3-540-49529-1_4.
6
The dose-response relationship in phase I clinical trials and beyond: use, meaning, and assessment.
Pharmacol Ther. 2000 Oct;88(1):33-58. doi: 10.1016/s0163-7258(00)00077-2.
7
[Estimation of EC50 in a sigmoidal dose-response curve with random effects].[具有随机效应的S型剂量反应曲线中EC50的估计]
Nihon Yakurigaku Zasshi. 2009 Jun;133(6):319-24. doi: 10.1254/fpj.133.319.
8
Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 2: data extrapolation, trial design, and pharmacokinetics.儿童溃疡性结肠炎药物临床开发协调的步骤——全球科学讨论,第2部分:数据外推、试验设计和药代动力学
J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):684-8. doi: 10.1097/MPG.0000000000000322.
9
Evaluating potential benefits of dose-exposure-response modeling for dose finding.评估剂量反应模型在剂量探索中的潜在益处。
Pharm Stat. 2009 Jul-Sep;8(3):203-15. doi: 10.1002/pst.392.
10
Dose-response of inhaled drugs in asthma. An update.哮喘中吸入药物的剂量反应。最新进展。
Clin Pharmacokinet. 1997 Jan;32(1):58-74. doi: 10.2165/00003088-199732010-00003.

本文引用的文献

1
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.厄贝沙坦对轻至中度高血压患者的剂量相关性降压作用。
Am J Hypertens. 1998 Apr;11(4 Pt 1):462-70. doi: 10.1016/s0895-7061(97)00501-3.
2
Prescription of cardiovascular drugs in outpatient care: a survey of outpatients in a German university hospital.德国一家大学医院门诊心血管药物处方情况:对门诊患者的一项调查
Int J Clin Pharmacol Ther. 1998 Apr;36(4):195-201.
3
Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
坎地沙坦酯,一种新一代血管紧张素II拮抗剂,具有剂量依赖性降压作用。
J Hum Hypertens. 1997 Sep;11 Suppl 2:S49-53.
4
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.缬沙坦。其药理学及在原发性高血压治疗应用的综述。
Drugs. 1997 Aug;54(2):299-311. doi: 10.2165/00003495-199754020-00009.
5
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.新型儿茶酚-O-甲基转移酶抑制剂托卡朋首次给人用药时的整合药代动力学和药效学
Clin Pharmacol Ther. 1995 May;57(5):508-17. doi: 10.1016/0009-9236(95)90035-7.
6
A guide to the pharmacology of placebos.安慰剂药理学指南。
Can Med Assoc J. 1983 Apr 15;128(8):921-5.
7
Dose-finding studies in clinical drug development.
Eur J Clin Pharmacol. 1988;34(1):15-9. doi: 10.1007/BF01061410.
8
Study designs for dose-ranging.
Clin Pharmacol Ther. 1989 Jul;46(1):63-77. doi: 10.1038/clpt.1989.108.
9
Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.苄氟噻嗪剂量、降压效果及不良生化效应之间的关系。
BMJ. 1990 Apr 14;300(6730):975-8. doi: 10.1136/bmj.300.6730.975.
10
How much drug in the tablet?片剂中含有多少药物?
Lancet. 1991 Feb 9;337(8737):346-8. doi: 10.1016/0140-6736(91)90958-r.